(AIM: SAR)

10 November 2014

SAREUM HOLDINGS PLC

(“Sareum” or the “Company”)

Notice of AGM

The Company announces that a notice has been sent to its shareholders to convene its Annual General Meeting (“AGM”) which is to be held at 10.00 a.m. on 17 December 2014 at the offices of Hybridan LLP, Birchin Court, 20 Birchin Lane, London EC3V 9DU.

In addition, and further to the announcement of the Company’s final results for the year ended 30 June 2014 released on 14 October 2014, the Company announces that the report and accounts have been posted to those shareholders that requested hard copies.

Both the report and accounts and the notice of AGM will be available on the Company’s website www.sareum.co.uk shortly.

Enquiries:

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

Sanlam Securities UK Limited (Nomad)

Simon Clements / James Thomas

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce / William Lynne

0203 713 4581/ 4582

The Communications Portfolio (Media enquiries)

 

Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk

020 7536 2028

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk